| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Assessing the lung cancer comorbidome: An analysis of German claims data
|
Murawski, Monika
|
|
2019
|
127 |
C |
p. 122-129
|
artikel
|
| 2 |
Association of oral health with lung cancer risk in a low-income population of African Americans and European Americans in the Southeastern United States
|
Yoon, Hyung-Suk
|
|
2019
|
127 |
C |
p. 90-95
|
artikel
|
| 3 |
Comment on: Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC
|
Xu, Ran
|
|
2019
|
127 |
C |
p. 167
|
artikel
|
| 4 |
Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer
|
Yu, Yongfeng
|
|
2019
|
127 |
C |
p. 19-24
|
artikel
|
| 5 |
Contents
|
|
|
2019
|
127 |
C |
p. v-vi
|
artikel
|
| 6 |
Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France
|
Chouaid, Christos
|
|
2019
|
127 |
C |
p. 44-52
|
artikel
|
| 7 |
Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China
|
Gu, Xiaohua
|
|
2019
|
127 |
C |
p. 84-89
|
artikel
|
| 8 |
Editorial Board
|
|
|
2019
|
127 |
C |
p. iii
|
artikel
|
| 9 |
Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations
|
Hasegawa, Hanako
|
|
2019
|
127 |
C |
p. 146-152
|
artikel
|
| 10 |
Feasibility of lung cancer RNA acquisition from a single transbronchial or transthoracic needle pass (FASTT trial)
|
Dotson, Travis
|
|
2019
|
127 |
C |
p. 6-11
|
artikel
|
| 11 |
High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients
|
Hsu, Kuo-Hsuan
|
|
2019
|
127 |
C |
p. 37-43
|
artikel
|
| 12 |
Histologic transformation of ALK-rearranged adenocarcinoma to squamous cell carcinoma after treatment with ALK inhibitor
|
Park, Sehhoon
|
|
2019
|
127 |
C |
p. 66-68
|
artikel
|
| 13 |
Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo)
|
Halmos, Balazs
|
|
2019
|
127 |
C |
p. 103-111
|
artikel
|
| 14 |
Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non–small cell lung cancer negative for EGFR mutation and ALK fusion
|
Sakai, Hitomi
|
|
2019
|
127 |
C |
p. 59-65
|
artikel
|
| 15 |
Leptomeningeal metastasis after effective first-generation EGFR TKI treatment of advanced non-small cell lung cancer
|
Wu, Ya-Lan
|
|
2019
|
127 |
C |
p. 1-5
|
artikel
|
| 16 |
Measurement and immunophenotyping of pleural fluid EpCAM-positive cells and clusters for the management of non-small cell lung cancer patients
|
Thompson, Jeffrey C.
|
|
2019
|
127 |
C |
p. 25-33
|
artikel
|
| 17 |
Molecular pathways and diagnosis in malignant mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group
|
Chapel, David B.
|
|
2019
|
127 |
C |
p. 69-75
|
artikel
|
| 18 |
Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional case
|
Roca, Elisa
|
|
2019
|
127 |
C |
p. 12-18
|
artikel
|
| 19 |
Outcomes of Stage III NSCLC with occult primary vs. known primary lesions
|
Romesser, Paul B.
|
|
2019
|
127 |
C |
p. 34-36
|
artikel
|
| 20 |
Post-treatment mortality after definitive chemoradiotherapy versus trimodality therapy for locally advanced non-small cell lung cancer
|
Haque, Waqar
|
|
2019
|
127 |
C |
p. 76-83
|
artikel
|
| 21 |
Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations
|
Tanaka, Ichidai
|
|
2019
|
127 |
C |
p. 169-171
|
artikel
|
| 22 |
Progress of malignant mesothelioma research in basic science: A review of the 14th international conference of the international mesothelioma interest group (iMig2018)
|
Wu, Licun
|
|
2019
|
127 |
C |
p. 138-145
|
artikel
|
| 23 |
Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models
|
Pyo, Kyoung Ho
|
|
2019
|
127 |
C |
p. 112-121
|
artikel
|
| 24 |
Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation
|
Auliac, Jean Bernard
|
|
2019
|
127 |
C |
p. 96-102
|
artikel
|
| 25 |
Real-world treatment patterns and outcomes of patients with small cell lung cancer progressing after 2 lines of therapy
|
Coutinho, Anna D.
|
|
2019
|
127 |
C |
p. 53-58
|
artikel
|
| 26 |
Reply to the comments on: Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC
|
Suh, Chong Hyun
|
|
2019
|
127 |
C |
p. 168
|
artikel
|
| 27 |
Retrospective response analysis of BAP1 expression to predict the clinical activity of systemic cytotoxic chemotherapy in mesothelioma
|
Kumar, Neelam
|
|
2019
|
127 |
C |
p. 164-166
|
artikel
|
| 28 |
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC
|
Mazzaschi, Giulia
|
|
2019
|
127 |
C |
p. 153-163
|
artikel
|
| 29 |
Variable impact of prior cancer history on the survival of lung cancer patients
|
Monsalve, Andres F.
|
|
2019
|
127 |
C |
p. 130-137
|
artikel
|
Tijdschrift beschrijving